ReviewMolecular biotechnology2026
Mesenchymal Stem/Stromal Cell-Free Therapies: Challenges and Opportunities.
Review in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Mesenchymal stem/stromal stem cells (MSCs) are promising therapeutic candidates in regenerative medicine and tissue engineering. MSCs have been applied in many medical conditions and their therapeutic effects, safety, and efficacy have been well established over the past few decades. However, several challenges exist when utilizing whole cells in research and the clinical settings. As a result, researchers have turned their attention to cell-free alternatives to overcome these challenges. One promising approach that can achieve the desired therapeutic effects without the need of whole-cell transplantation is the use of MSC-conditioned medium and secretome. This article gives an overview of the advantages of using cell-free strategies over cell-based strategies and the various types of cell-free alternatives available. It also critically examines the various cell-free approaches in MSC research and therapy and provides an in-depth discussion on the opportunities and challenges of using these strategies, with an emphasis on recent advances in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.